Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

Published:2024-09 Issue:3 Volume:86 Page:280-281
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Klümper Niklas^ORCID,Vera-Badillo Francisco E.,Eckstein Markus,Hadaschik Boris,Grünwald Viktor

Publisher

Elsevier BV

Reference7 articles.

1. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer;Powles;N Engl J Med,2024

2. Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma;van der Heijden;N Engl J Med,2023

3. Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy;Sridhar;J Clin Oncol,2023

4. EV-101: a phase I study of single-agent enfortumab vedotin in patients with nectin-4–positive solid tumors, including metastatic urothelial carcinoma;Rosenberg;J Clin Oncol,2020

5. Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance;Klümper;Clin Cancer Res,2023

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reevaluating the role of platinum-based chemotherapy in the evolving treatment landscape for patients with advanced urothelial carcinoma;The Oncologist;2024-08-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3